An update on lipid profile screening in second-generation antipsychotic users in the USA

References

• Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatrica Scandinavica 121(1), 4–10 (2010).
   Google Scholar
• Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995–2008.Pharmacoepidemiol. Drug Saf. 20(2), 177–184 (2011).
   Google Scholar
• Lindsley CW. The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing. ACS Chem. Neurosci. 1(6), 407–408 (2010).
   Google Scholar
• Zuvekas S. Prescription drugs and the changing patterns of treatment for mental disorders, 1996–2001. Health Aff. (Millwood) 24, 195–205 (2005).
   Google Scholar
• Walton S, Schumock G, Lee K-V, Alexander G, Meltzer D, Stafford R. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy 28(12), 1443–1452 (2008).
   Google Scholar
• Abilify®, prescribing information. Otsuka Inc., MD, USA (2012).
   Google Scholar
• Geodon®, prescribing information. Pfizer Inc., NY, USA (2012).
   Google Scholar
• Zyprexa®, prescribing information. Lilly Inc., IN, USA (2009).
   Google Scholar
• Seroquel®, prescribing information, Astrazeneca, London, UK (2012).
   Google Scholar
• Risperdal®, prescribing information, Janssen, Division of Ortho-Mcneil-Janssen Pharmaceuticals Inc., Antwerp, Belguim (2012).
   Google Scholar
• Walton SM, Schumock GT, Lee K, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation.Pharmacotherapy 28(12), 1443–1452 (2008).
   Google Scholar
• Pathak P, West D, Martin BC, Helm ME, Henderson C. Evidence-based use of second-generation antipsychotics in a state medicaid pediatric population, 2001–2005.Psychiatr. Serv. 61(2), 123–129 (2010).
   Google Scholar
• Leslie DL, Rosenheck R. Off-label use of antipsychotic medications in medicaid. Am. J. Manag. Care 18(3), e109–e117 (2012).
   Google Scholar
• Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 298(15), 1794–1796 (2007).
   Google Scholar
• Goff DC, Sullivan LM, McEvoy JP et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 80(1), 45–53 (2005).
   Google Scholar
• Druss BG, Zhao L, Von Esenwein S, Morrato EH, Marcus SC. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med. Care 49(6), 599–604 (2011).
   Google Scholar
• Colton C, Manderscheid R. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic Dis. 3(2), A42 (2006).
   Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl. 1), 1–93 (2005).
   Google Scholar
• McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.Can. J. Psychiatry 46(3), 273–281 (2001).
   Google Scholar
• McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schiz. Res. 80(1), 19–32 (2005).
   Google Scholar
• Holt RI, Abdelrahman T, Hirsch M et al. The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. J. Psychopharmacol. 24(6), 867–873 (2010).
   Google Scholar
• Frayne SM, Halanych JH, Miller DR et al. Disparities in diabetes care: impact of mental illness. Arch. Intern. Med. 165(22), 2631–2638 (2005).
   Google Scholar
• Nasrallah HA, Meyer JM, Goff DC et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 86(1–3), 15–22 (2006).
   Google Scholar
• Falissard B, Mauri M, Shaw K et al. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int. Clin. Psychopharmacol. 26(6), 291–302 (2011).
   Google Scholar
• Correll CU, Druss B, Lombardo I et al. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr. Serv. 61(9), 892–898 (2010).
   Google Scholar
• De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 8(2), 114–126 (2012).
   Google Scholar
• Newcomer JW, Haupt DW, Fucetola R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.Arch. Gen. Psychiatry 59(4), 337–345 (2002).
   Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657), 31–41 (2009).
   Google Scholar
• Meyer JM, Davis VG, Goff DC et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from Phase 1. Schiz. Res. 101(1–3), 273–286 (2008).
   Google Scholar
• Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schiz. Res. 70(1), 1–17 (2004).
   Google Scholar
• Birkenaes AB, Birkeland KI, Engh JA et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J. Clin. Psychopharmacol. 28(2), 132–137 (2008).
   Google Scholar
• Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur. Neuropsychopharmacol. 19(9), 629–635 (2009).
   Google Scholar
• Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann. Pharmacother. 42(9), 1316–1322 (2008).
   Google Scholar
• McIntyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch. Pediatr. Adolesc. Med. 162(10), 929–935 (2008).
   Google Scholar
• Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents.J. Am. Acad. Child Adolesc. Psychiatry 45(7), 771–791 (2006).
   Google Scholar
• Arango C, Robles O, Parellada M et al. Olanzapine compared with quetiapine in adolescents with a first psychotic episode. Eur. Child Adolesc. Psychiatry 18(7), 418–428 (2009).
   Google Scholar
• Khan RA, Mican LM, Suehs BT. Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation. J. Psychiatr. Pract. 15(4), 320–328 (2009).
   Google Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302(16), 1765–1773 (2009).
   Google Scholar
• Cassels C. A typical antipsychotics linked to rapid, adverse metabolic changes in children.Medscape Medical News, 11th April 2009.
   Google Scholar
• Ho J, Panagiotopoulos C, Mccrindle B, Grisaru S, Pringsheim T, Group CG. Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J. Can. Acad. Child Adolesc. Psychiatry 20(3), 234–241 (2011).
   Google Scholar
• US FDA. Warning about hyperglycemia and atypical antipsychotic drugs. FDA Safety News, Show #28, June 2004.
   Google Scholar
• Rosack J. FDA to require diabetes warning on antipsychotics. Psychiatr. News 38(20), 1 (2003).
   Google Scholar
• De Hert M, Vancampfort D, Correll CU et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br. J. Psychiatry 199(2), 99–105 (2011).
   Google Scholar
• Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM. Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schiz. Res. 79(281–288), (2005). ▪ Describes physician awareness of dyslipidemia risks with second-generation antipsychotic (SGA) medications and self-reported rates of lipid profile testing, based on a sample of psychiatrists surveyed in the USA.
   Google Scholar
• Ketter TA, Haupt DW. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice.Curr. Med. Res. Opin. 22(12), 2345–2353 (2006).
   Google Scholar
• Suppes T, McElvoy S, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 U.S. psychiatrists.Psychopharmacol. Bull. 40(2), 22–37 (2007).
   Google Scholar
• Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J. Clin. Psychopharmacol. 24(5 Suppl. 1), S1–S6 (2004).
   Google Scholar
• Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am. J. Psychiatry 166(3), 345–353 (2009). ▪▪ Demonstrated the minimal effect of the US FDA diabetes warnings and SGA Consensus Statement on lipid profile testing in a national sample of commercially insured patients.
   Google Scholar
• Campbell EC, Dejesus M, Herman BK et al. A pilot study of antipsychotic prescribing decisions for acutely ill hospitalized patients.Prog. Neuropsychopharmacol. Biol. Psychiatry 35(1), 246–251 (2011).
   Google Scholar
• Morrato EH, Cuffel B, Newcomer JW, Lombard I, Kamat S, Barron J. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J. Clin. Psychopharmacol. 29(1), 26–32 (2009).
   Google Scholar
• Morrato EH, Druss BG, Hartung DM et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch. Gen. Psychiatry 67(1), 17–24 (2010).
   Google Scholar
• Constantine R, Tandon R. Changing trends in pediatric antipsychotic use in Florida’s Medicaid program. Psych. Serv. 59(10), 1162–1168 (2008).
   Google Scholar
• Li C, Mittal D, Owen RR. Impact of patients’ preexisting metabolic risk factors on the choice of antipsychotics by office-based physicians.Psychiatr. Serv. 62(12), 1477–1484 (2011).
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143–3421 (2002).
   Google Scholar
• De Hert M, Kalnicka D, van Winkel R et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 67(12), 1889–1896 (2006).
   Google Scholar
• Ojala K, Repo-Tiihonen E, Tiihonen J, Niskanen L. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents.J. Psychopharmacol. 22(1), 33–38 (2008).
   Google Scholar
• National Center for Health Statistics (US). Health, United States, 2010: with special feature on death and dying. National Center for Health Statistics (US) 2011–1232 (2011).
   Google Scholar
• Wu RR, Jin H, Gao K et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry 169(8), 813–821 (2012).
   Google Scholar
• Wu RR, Zhao JP, Jin H et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 299(2), 185–193 (2008).
   Google Scholar
• Wu RR, Zhao JP, Guo XF et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am. J. Psychiatry 165(3), 352–358 (2008).
   Google Scholar
• Baptista T, Martinez J, Lacruz A et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can. J. Psychiatry 51(3), 192–196 (2006).
   Google Scholar
• Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int. Clin. Psychopharmacol. 27(2), 69–75 (2012).
   Google Scholar
• Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers.Curr. Psychiatry Rev. 8(1), 25–36 (2012).
   Google Scholar
• Hsu C, Ried LD, Bengtson MA, Garman PM, McConkey JR, Rahnavard F. Metabolic monitoring in veterans with schizophreniarelated disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. J. Am. Pharm. Assoc. 48(3), 393–400 (2008).
   Google Scholar
• Morrato EH, Nicol GE, Maahs D et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch. Pediatr. Adolesc. Med. 164(4), 344–351 (2010). ▪▪ Demonstrated very low rates of lipid profile testing among children receiving SGA medication in the USA in three state Medicaid programs.
   Google Scholar
• Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the ADA’s Consensus Statement on antipsychotic drugs and diabetes. Diabetes Care 32(6), 1037–1042 (2009).
   Google Scholar
• Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol. Med. 42(1), 125–147 (2012). ▪▪ Provides a meta-analysis of studies published on cardiometabolic risk monitoring (including weight, blood pressure and serum glucose and lipids) before and after guidelines, among persons with serious mental illness.
   Google Scholar
• Moeller KE, Rigler SK, Mayorga A, Nazir N, Shireman TI. Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance. Schizophr. Res. 126(1–3), 117–123 (2011).
   Google Scholar
• Kuehn BM. Studies shed light on risks and trends in pediatric antipsychotic prescribing.JAMA 303(19), 1901–1903 (2010).
   Google Scholar
• De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur. Psychiatry 26(3), 144–158 (2011).
   Google Scholar
• Morrato EH, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J. Clin. Psychiatry 69, 316–322 (2008).
   Google Scholar
• Morrato EH, Druss BG, Hartung DM et al. Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users.Pharmacoepidemiol. Drug Saf. 20(1), 66–75 (2011).
   Google Scholar
• Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, Fonseca V, Winstead D. Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry 9, 80 (2009).
   Google Scholar
• Motsinger C, Slack M, Weaver M, Reed M. Physician patterns of metabolic screening for patients taking atypical antipsychotics: a retrospective database study. Prim. Care Companion J. Clin. Psychiatry 67, 220–223 (2006).
   Google Scholar
• Jerrell JM, McIntyre RS, Black GB. Economic grand rounds: economic costs of failure to monitor adverse effects of second-generation antipsychotics: an underestimated factor. Psychiatr. Serv. 63(3), 202–204 (2012). ▪ Describes the limited state of system-level improvements to facilitate adherence to screening guidelines in major public and private mental health treatment settings.
   Google Scholar
• De Hert M, Cohen D, Bobes J et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10(2), 138–151 (2011). ▪ Provides a review of barriers affecting the adoption of cardiometabolic risk monitoring among psychiatric practices in developed and developing nations.
   Google Scholar
• Dragatsi D, Deakins SM. Case studies in public-sector leadership: implementing a metabolic initiative in a community mental health clinic. Psychiatr. Serv. 60(10), 1298–1301 (2009).
   Google Scholar
• Nicol G, Morrato E, Johnson MC et al. Successful implementation of a “best practice” glucose screening program based on lean six sigma and diffusion of innovation methods. Psychiatr. Serv. 62(1), 12–14 (2011).
   Google Scholar
• Torres DM. Evidence-based monitoring for metabolic syndrome in clients with chronic schizophrenia. J. Healthc. Qual. 29(2), 48–56 (2007).
   Google Scholar
• Schneiderhan ME, Batscha CL, Rosen R. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy 29(8), 975–987 (2009).
   Google Scholar
• Vanderlip ER, Fiedorowicz JG, Haynes WG. Screening, diagnosis, and treatment of dyslipidemia among persons with persistent mental illness: a literature review. Psychiatr. Serv. 63(7), 693–701 (2012) .
   Google Scholar
• Schuffman D, Druss BG, Parks JJ. State Mental Health Policy: mending Missouri’s safety net: transforming systems of care by integrating primary and behavioral health care. Psychiatr. Serv. 60(5), 585–588 (2009).
   Google Scholar
• Weissman EM, Zhu CW, Schooler NR, Goetz RR, Essock SM. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. J. Clin. Psychiatry 67(9), 1323–1326 (2006).
   Google Scholar
• Barnett M, Vonmuenster S, Wehring H et al. Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics. Ann. Clin. Psychiatry 22(1), 9–18 (2010).
   Google Scholar
• Weissman EM, Jackson C, Schooler NR, Goetz RR, Essock SM. Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication.Clin. Schizophr. Relat. Psychoses 5(4), 201–207 (2011).
   Google Scholar
• Kilbourne AM, Post EP, Bauer MS et al. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. J. Affect. Disord. 102(1–3), 145–151 (2007). ▪▪ Demonstrated low rates of annual lipid profile testing in a national sample of 107 medical centers in the US Veterans Affairs administration.
   Google Scholar
• Khatana SA, Kane J, Taveira TH, Bauer MS, Wu WC. Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PloS ONE 6(4), e19298 (2011).
   Google Scholar
• Kilbourne AM, Lai Z, Bowersox N, Pirraglia P, Bauer MS. Does colocated care improve access to cardiometabolic screening for patients with serious mental illness? Gen. Hosp. Psychiatry 33(6), 634–636 (2011).
   Google Scholar
• Batscha C, Schneiderhan ME, Kataria Y, Rosen C, Marvin RW. Treatment settings and metabolic monitoring for people experiencing first-episode psychosis. J. Psychosoc. Nurs. Ment. Health Serv. 48(9), 44–49 (2010).
   Google Scholar
• Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J. Clin. Psychiatry 68(Suppl. 4), 40–44 (2007).
   Google Scholar
• Dunbar L, Brandt T, Wheeler A, Harrison J. Barriers and solutions to implementing metabolic risk assessment in a secondary mental health service. Australas. Psychiatry 18(4), 322–325 (2010).
   Google Scholar
• Sernyak MJ. Implementation of monitoring and manaement guidelines for second-generation antipsychotics. J. Clin. Psychiatry 68(Suppl. 4), 14–18 (2007).
   Google Scholar
• Walter G, Delaroche A, Soh N et al. Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists.Australas. Psychiatry 16(4), 253–262 (2008).
   Google Scholar